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VUKMANOVIC-STEJIC ET AL 845Background: Immunity decreases with age, which leads to
reactivation of varicella zoster virus (VZV). In human subjects
age-associated immune changes are usually measured in blood
leukocytes; however, this might not reflect alterations in tissue-
specific immunity.
Objectives: We used a VZV antigen challenge system in the skin
to investigate changes in tissue-specific mechanisms involved in
the decreased response to this virus during aging.
Methods: We assessed cutaneous immunity based on the extent
of erythema and induration after intradermal VZV antigen
injection. We also performed immune histology and
transcriptomic analyses on skin biopsy specimens taken from
the challenge site in young (<40 years) and old (>65 years)
subjects.
Results: Old human subjects exhibited decreased erythema and
induration, CD41 and CD81 T-cell infiltration, and attenuated
global gene activation at the site of cutaneous VZV antigen
challenge compared with young subjects. This was associated
with increased sterile inflammation in the skin in the same
subjects related to p38 mitogen-activated protein kinase–related
proinflammatory cytokine production (P < .0007). We inhibited
systemic inflammation in old subjects by means of pretreatment
with an oral small-molecule p38 mitogen-activated protein kinase
inhibitor (Losmapimod; GlaxoSmithKline, Brentford, United
Kingdom), which reduced both serum C-reactive protein levels
and peripheral blood monocyte secretion of IL-6 and TNF-a. In
contrast, cutaneous responses to VZV antigen challenge were
increased significantly in the same subjects (P < .0003).
Conclusion: Excessive inflammation in the skin early after
antigen challenge retards antigen-specific immunity. However,
this can be reversed by inhibition of inflammatory cytokine
production that can be used to promote vaccine efficacy and the
treatment of infections and malignancy during aging. (J Allergy
Clin Immunol 2018;142:844-56.)
Key words: Aging, p38 mitogen-activated protein kinase, varicella
zoster virus, inflammation
Older subjects have reduced immune function that predisposes
them to an increased incidence of infection and malignancy.1,2 In
addition, vaccine efficacy against many pathogens is also reduced
in these subjects.3 We developed a human experimental system to
investigate antigen-specific immunity in vivo in which healthy
volunteers are challenged intradermally to induce antigen-
specific delayed-type hypersensitivity responses. This enabled
the investigation of the kinetics and specificity of memory T-
cell expansion and the interactions between different leukocytes
after a single episode of immune stimulation in situ.4-6
Varicella zoster virus (VZV) is an a-herpesvirus that causes
chickenpox. After resolution of the initial infection, VZV
becomes latent within dorsal root ganglia but reactivates in older
subjects causing herpes zoster (shingles).7,8 During both primary
infection and latent virus reactivation, the absence of T-cell im-
munity results in VZV-induced pathology.9,10 Therefore
decreased skin responsiveness to VZV challenge is a good model
for investigating immune decline during aging.
Old subjects exhibited reduced erythema and induration
(clinical response) after injection of a VZV skin test antigen
that was correlated with decreased T-cell infiltration and prolif-
eration in the skin. This was not due to defective macrophageactivation4 or reduced inherent function of skin-resident memory
T (TRM) cells.
11 On the contrary, we identified a propensity of the
skin of old but not young subjects to mount an overexuberant
proinflammatory response on sterile challenge with a physiolog-
ical saline solution. This was significantly inversely correlated
with decreased VZVantigen responsiveness in the same subjects.
Previous studies demonstrated that systemic inflammation, as
indicated by increased levels of serum IL-6, TNF-a, and
C-reactive protein (CRP), are strong predictors for frailty and
mortality during aging.12,13 Ingenuity Pathway Analysis
indicated a significant association between the inflammatory
gene in the skin of old subjects with p38 mitogen-activated
protein (MAP) kinase pathway activation (P 5 1 3 10218).
We tested the hypothesis that the magnitude of the
sterile proinflammatory response in the skin and reduced
antigen-specific immunity in the same subjects was linked. To
do this, we treated old human subjects with the oral p38 MAP
kinase inhibitor Losmapimod (GlaxoSmithKline, Brentford,
United Kingdom) for 4 days to inhibit proinflammatory cytokine
production. This resulted in a significant reduction in CRP levels
and peripheral blood monocyte secretion of IL-6 and TNF-a after
stimulation in vitro but a significantly increased response to
cutaneous VZV antigen challenge in the same subjects. Thus
decreased VZV antigen challenge responsiveness in the skin of
old subjects is related to excessive proinflammatory responses.
Therefore anti-inflammatory intervention might be a strategy
for boosting cutaneous immunity during aging.METHODS
Study design
This work was approved by the Ethics Committee of Queen Square
(London, UnitedKingdom) and by the institutional review board (UCLR&D).
Healthy young subjects (<40 years of age; n5 97; median age, 29 years) and
old subjects (>65 years of age; n5 78; median age, 75.5 years) were recruited
(see Tables E1 and E2 in this article’s Online Repository at www.jacionline.
org). Exclusion criteria are described in the Methods section in this article’s
Online Repository at www.jacionline.org. All volunteers provided written
informed consent, and study procedures were performed in accordance with
the principles of the Declaration of Helsinki.Skin tests
VZVantigen (BIKEN, the Research Foundation for Microbial Diseases of
Osaka University, Osaka, Japan) was injected intradermally into sun-
unexposed skin of the medial proximal volar forearm, according to the
manufacturer’s instructions. Induration, palpability, and the change in ery-
thema from baseline were measured and scored on day 3, as described
previously.14 A clinical score (range, 0-10) based on the summation of these
parameters was then calculated.14 The injection site was sampled by means
of skin biopsy at different times after injection with VZV skin test antigen.
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A subgroup of 18 old volunteers (8 male and 10 female subjects; age range,
65-77 years; median age, 69 years) were subjected to VZV antigen skin
testing, as described above. Approximately 2 to 3 months later, volunteers
received 15 mg of Losmapimod (GW856553) twice daily for 4 days (provided
by GlaxoSmithKline under a Medical Research Council Industrial Collabo-
ration Agreement). The dose of 15 mg of Losmapimod twice daily used in this
study was chosen on the basis of the pharmacokinetic, pharmacodynamic, and
safety profiles of Losmapimod observed in GlaxoSmithKline phase I and II
studies.15
On day 4 of Losmapimod treatment, VZV skin test antigen was injected
intradermally, and clinical scores were recorded 48 hours later, as before.
A history of liver disease or increased liver transaminase levels (>1.5 times the
upper limit of normal) and abnormal electrocardiographic results were
additional exclusion criteria for this part of the study. Serum CRP levels
were measured by using a high-sensitivity assay.16
To assess compliance, ex vivo whole-blood LPS stimulation assays
were performed before and 4 days after Losmapimod treatment.17
Briefly, peripheral blood was cultured with LPS (0-1 mg/mL) for 24 hours
(378C in a 5% CO2 atmosphere). Levels of TNF-a and IL-6 in plasma
were assessed by using the Cytometric Bead Array (CBA; BD, San Jose,
Calif).Skin biopsies
Punch biopsy specimens (5 mm in diameter) from the site of antigen
injection were obtained from young and old volunteers at various time points
(as indicated) after VZV skin test antigen injection. Control skin punch biopsy
specimens from normal (uninjected) forearm skin were also obtained. Biopsy
specimens were frozen in OCT compound (Bright Instrument Company,
Luton, Belgium), as previously described.4,11 Six-micrometer sections were
cut and left to dry overnight and then fixed in ethanol and acetone and stored
at 2808C.Immunohistochemistry
Skin sections from normal, VZV skin test antigen–injected, or saline-
injected skin were stained with optimal dilutions of primary antibodies, as
previously described (see Table E3 in this article’s Online Repository at www.
jacionline.org).4,11 The number of positively stained cells per square milli-
meter was counted manually by using computer-assisted image analysis
(National Institutes of Health Image software 6.1; http://rsb.info.nih.gov/
nih-image). Cell numbers were expressed as the mean absolute cell number
counted within the frame.Immunofluorescence
Sections were stained with optimal dilutions of primary antibodies and
followed by an appropriate secondary antibody conjugated to various
fluorochromes, as previously described (see Table E4 in this article’s Online
Repository at www.jacionline.org).4,11 The number of cells in 5 of the largest
perivascular infiltrates present in the upper and middle dermis were selected
for analysis, and an average was calculated.18 Macrophage images were
imaged on the AxioScan Z1 slide scanner and Imaged on Zen Blue (Zeiss,
Cambridge, United Kingdom).Skin biopsy digestion for flow cytometric analysis
Skin biopsy specimens (5 mm) were taken from normal and saline-
injected skin (6 hours after injection) and disaggregated by means of
overnight incubation (378C in a 5% CO2 atmosphere) in 0.8 mg/mL
collagenase IV (Sigma-Aldrich, St Louis, Mo) with 20% FCS. Single-
cell suspensions were obtained by filtering the suspension through 100-
, 70-, and 40-mm filters. Cells derived from skin biopsy specimens
were assessed by using flow cytometric analysis on a BD Fortessa
with FACSDiva software (BD Biosciences) and subsequently analyzed
with FlowJo software (version X; TreeStar, Ashland, Ore). For detailsof antibodies used, see Table E5 in this article’s Online Repository at
www.jacionline.org.CBA
IL-6, IL-8, and TNF-a plasma concentrations were measured by using
CBA (BD), according to the manufacturer’s protocol. The lower limit of
detection for each analyte was 1.5 pg/mL.Transcriptional analyses
Three-millimeter punch biopsy specimens were collected from the injection
site 6 or 72 hours after injection with VZVantigen or normal saline and frozen
immediately in RNAlater. Normal (uninjected) skin from the same site was
collected as a control. Frozen tissue was homogenized, and total RNA was
extracted from bulk tissue homogenates by using the RNeasy Mini Kit (Qiagen,
Hilden, Germany). Details of gene expression analyses are provided in the
Methods section in this article’s Online Repository.
Where indicated, human skin-punchmicroarray data were combinedwith a
large collection of other primary cell gene-expression data sets (745 individual
microarray data sets) available from the Gene Expression Omnibus database
on the same Affymetrix Human Genome U133 Plus 2.0 expression array
platform (Affymetrix, Santa Clara, Calif). The entire collection of primary cell
expression data are available through Gene Expression Omnibus accession
number GSE49910. Full details of each primary cell data set have been pub-
lished.19 Upstream regulator analysis was performed with Ingenuity Pathway
Analysis (Qiagen).Statistics
Statistical analysis was performed with GraphPad Prism software (version
6.00; GraphPad Software, San Diego, Calif). Paired or unpaired t tests were
used when data were normally distributed, and nonparametric tests were
used when data were not normally distributed. The Kruskal-Wallis test was
used to compare 3 or more unpaired groups, and a 2-tailed Mann-Whitney
test was usedwhen comparing only 2 unpaired groups. TheWilcoxonmatched
pairs test was used when comparing 2 groups of matched data. Two-way
ANOVAwas used to compare the effects of Losmapimod and LPS.RESULTS
Decreased response to VZV challenge in the skin
during aging
We investigated the cutaneous response of young (<40 years)
and old (>65 years) volunteers to VZVantigen skin challenge. All
volunteers had a prior history of chickenpox. At 72 hours after
VZV injection, young subjects had obvious erythema and
induration (clinical responses), whereas the clinical response of
old subjects was significantly less and correlated inversely with
increasing age (P < .0001, n 5 184; young, n 5 97; old, n 5 78;
middle age [40-65 years], n5 14; Fig 1, A; see Fig E1 in this ar-
ticle’s Online Repository at www.jacionline.org; for participant
details, see Tables E1 and E2). There were no differences in the
response of male and female donors in the young and old age
groups (P 5 .5, see Table E2). The decrease in clinical score
was associated with decreased CD41 T-cell accumulation at the
site of VZV challenge in the skin at all time points investigated
(Fig 1, B-D). There was a highly significant correlation between
the clinical score (measured at 72 hours) and the extent of
CD41 T-cell accumulation in old subjects (measured at 7 days;
Fig 1, E). We stratified old subjects into those who had a low
skin response to VZV (clinical score, <4; 88% of old volunteers)
and those with responses similar to those of young subjects with a
clinical score of greater than 4 (86% of young volunteers).
FIG 1. Cutaneous response to VZV antigen is reduced in old subjects. Healthy young and old volunteers
were injected with VZV skin antigen. Circles, Female subjects; diamonds, male subjects. Clinical score at day
3 in response to VZV was calculated based on induration, palpability, and redness. A, Clinical score versus
participant’s age. B, Hematoxylin and eosin staining (310 magnification). PV, Perivascular infiltrates. Five-
millimeter punch biopsies were performed on days 0, 1, 3, or 7 after injection (with 4-7 volunteers per time
point). C, Representative skin sections stained for CD4 (green; original magnification3400). D, Collated data
of T-cell numbers at different times after VZV injection in young and old volunteers. Each symbol represents
the average number of CD41 T cells within perivascular infiltrates for each subject (n 5 4-7 per time point;
Mann-Whitney test; horizontal bar represents the mean). E, Clinical score at 48 hours (peak clinical
response) correlated with the number of CD41 T cells in the perivascular infiltrate at the peak of cellular
response on day 7 (n 5 10 young [solid circles] and 22 old [open circles] subjects). *P < .05, **P < .01,
and ***P < .001. ns, Not significant.
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not related to differences in numbers of resident memory CD41 or
CD81 T cells defined by expression of CD69 alone or the combi-
nation of CD69 and CD10320,21 in the skin of young and old sub-
jects (see Fig E2 in this article’s Online Repository at www.
jacionline.org).11Reduced dendritic cell/T-cell interaction and T-cell
proliferation after VZV challenge in old subjects
Immune clusters containing both antigen-presenting cells
and T cells (referred to as skin-associated lymphoid tissue) are
generated in the skin during cutaneous immune responses.22A highly significant increase in the number of CD11c1 den-
dritic cells (DCs) was observed in the skin of young but not
old subjects at different times after VZV antigen challenge
(Fig 2, A and B). DCs accumulate around blood vessels and
form large perivascular clusters with CD41 T cells (Fig 2,
C) and, to a lesser extent, CD81 T cells (data not shown).
By 3 days after VZV antigen challenge, the majority of DCs
within these infiltrates in the skin of young subjects were
CD1c2 and expressed DC-lysosome–associated membrane
glycoprotein, a marker of mature inflammatory DCs. In the
skin of old subjects after VZV antigen challenge, DC infiltra-
tion was significantly reduced compared with that in the young
group (Fig 2, A and B).
FIG 2. Perivascular cluster formation is reduced in the skin of old subjects. Five-millimeter punch biopsies
were performed on days 0, 1, 3, or 7 after VZV injection (with 3-6 volunteers per time point). A, Represen-
tative staining of skin sections immunostained for CD11c (original magnification 310). B, Cumulative
data showing mean CD11c1 cell numbers per field (solid bars, young subjects; open bars, old subjects).
Data are shown as means 6 SEMs. *P < .05 and **P < .01. C, Representative staining showing CD11c1
DCs (red) and CD41 T cells (green) in a perivascular cluster (representative young donor on day 3 after
VZV injection, 3400 magnification). Dapi, 49-6-Diamidino-2-phenylindole dihydrochloride.
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detectable in normal skin, but a significant increase was observed
from 3 days after VZVantigen challenge compared with baseline
values (see Fig E3, A and B, in this article’s Online Repository at
www.jacionline.org). Proliferation of CD81 T cells was also
observed, although to a lesser extent than for CD41 T cells (see
Fig E3, C and D). In contrast, in the skin of old subjects CD41
and CD81 T-cell proliferation was extremely low, even after
7 days of VZV antigen challenge (see Fig E3). This indicates
that in young subjects the increased accumulation of T cells in
the skin after VZVantigen challenge occurs in part from their pro-
liferation at the site of injection.
We investigated whether decreased endothelial cell activation
contributed to the reduced T-cell infiltration in the skin of old
subjects. At 6 hours after VZV antigen injection, 20% of the
CD311 capillary loops in young and old skin expressed both E-se-
lectin and vascular cell adhesion molecule 1, levels of which were
significantly greater than those observed in unchallenged (day 0)
skin from either age group (see Fig E4 in this article’s Online Re-
pository at www.jacionline.org). This suggests that endothelial
cells in old subjects are not defective and can be activated tothe same extent as young subjects early in the response. At later
time points, capillary loops in young subjects showed signifi-
cantly increased expression of E-selectin when compared with
those in old subjects (see Fig E4). Therefore reduced response
to VZV antigen challenge was not due to defects in initiation of
the response but was related to either active inhibition, lack of im-
mune amplification at later stages, or both.Global decrease in the magnitude of gene
expression in skin after VZV challenge in old
subjects
We next performed global gene expression analyses to identify
genes that might be associated with the decreased response to
VZV antigen challenge in old subjects. In each young or old
donor, skin punch biopsy specimens were taken from the site of
either VZV antigen challenge (6 and 72 hours after injection) or
saline injection (6 and 72 hours after injection; control) in the
contralateral arm of the same subjects (resulting in a total of 4
biopsy specimens per subjects). Gene expression was compared
with the signature in biopsy specimens taken from normal
FIG 3. Transcriptomic analysis of skin from young and old subjects after VZV antigen challenge. Three-
millimeter punch biopsy specimens were collected from old (n 5 10) and young (n 5 6) subjects at 6 and
72 hours after VZV injection. Normal skin punch biopsy specimens were collected from an additional group
of young (n 5 9) and old (n 5 6) subjects. Total skin RNA was isolated, amplified, and hybridized to
Affymetrix Human Genome U133 2.0 plus arrays. A, Heat map showing relative expression of DEGs be-
tween VZV-injected and normal skin from young (left) and old (right) subjects at a fold change (FCH) of
greater than 2 and a false discovery rate of greater than 0.05 in normal/unmanipulated skin and skin 6
and 72 hours after VZV challenge in each group. For each gene, only the probe set with the largest average
expression is shown. Unsupervised clustering was carried out by using Pearson correlation distance with
the McQuitty agglomeration scheme of DEGs at 6 hours after VZV. B, The table shows the top 30 upregu-
lated genes at 72 hours in young and old subjects compared with normal skin in each group.
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vious study we showed that there was no evidence for inflamma-
tory responses in either group at steady state.11
Six hours after VZV antigen challenge, there were 935
significantly upregulated and 1042 downregulated genes in the
skin of young subjects and 820 upregulated and 550 down-
regulated genes in the old group (see Fig E5, A, in this article’s
Online Repository at www.jacionline.org). Although similar
pathways were activated in the skin of young and old subjects
at 6 hours after VZV antigen challenge, the magnitude of their
expression was reduced in the old group (see Fig E5, B and C).At 72 hours after VZV antigen challenge, young subjects ex-
hibited a strong transcriptional response that was considerably
reduced in the old group (>5000 differentially expressed genes
[DEGs] in the young and 666 DEGs in the old group, Fig 3).
The top 30 genes that are significantly differentially expressed
are shown in Fig 4, B, indicating that the same genes are upregu-
lated in both groups but that the expression was reduced in the old
subjects, indicating attenuated immune amplification. Genes
associated with T-cell and DC activation, including ITGAX
(which encodes CD11c), CD2, CD28, CD69, CD83, CD86,
EOMES, ICOS, and STAT1, were more highly expressed in the
FIG 4. Comparison of global gene expression between normal, saline-injected, and VZV antigen–injected
skin. A, Schematic representation of biopsy collection for transcriptional analysis. B, Heat map showing
relative expression of DEGs (fold change [FCH] > 2 and false discovery rate > 0.05) between normal skin
and saline-injected skin at 6 hours after treatment in young (left) and old (right) subjects. C, The table shows
the top 20 upregulated genes at 6 hours in saline-injected skin from old and young subjects compared with
normal skin. Genes not reaching statistical significance are indicated in blue. Asterisks indicate genes
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VUKMANOVIC-STEJIC ET AL 851skin at 72 hours of VZV challenge in the young group compared
with the old group (see Table E6 in this article’s Online Reposi-
tory at www.jacionline.org). There was activation of signaling
pathways associated with immune responses, inflammation and
immune response to viruses, and pathways induced by type I in-
terferons and IFN-g signaling in young but not old subjects (see
Fig E5).Saline injection induces an inflammatory response
in old donors, which correlates inversely with
cutaneous VZV response
Sterile saline solution was a physiological control injected into
the contralateral arms of the same subjects who received VZV
skin antigen challenge (Fig 4, A). In young subjects saline injec-
tion had a negligible effect on gene expression compared with
normal skin (30 DEGs at 6 hours after injection; Fig 4, A and
B). However, in old subjects saline injection induced significant
early expression of numerous inflammatory genes (856 DEGs;
false discovery rate < 0.05; fold change > 2; Fig 4, A and B; see
Table E7 in this article’s Online Repository at www.jacionline.
org), including IL6, CXCL8, and PTX3, and also genes indicative
of myeloid cell activation, including CXCL2, IL1B, ICAM1, and
FCGR3A (Fig 4, B, and see Table E7).
Using Ingenuity Pathway Analysis, we found a significant
association with predicted p38 MAP kinase pathway activation
(P5 13 10218) when the genes that were upregulated after saline
injection (6 hours) in old skin were compared with unchallenged
control old skin. The majority of the top 30 genes activated after
6 hours of saline injection (Fig 4, C, asterisks) are induced by p38
MAP kinase signaling or are regulators of p38 MAP kinase acti-
vation. Furthermore, pathway analysis suggested that the
response to saline in the skin of old subjects involved the activa-
tion of inflammatory pathways relating to type I interferon pro-
duction, TNF-a signaling, MAP kinase activation, IFN-g
responses, and IL-17 production (Fig 4, D). Principal component
analysis demonstrated that gene expression in response to saline
injection in young and old subjects was distinct (see Fig E6, B)
and that a large number of the genes that were upregulated by
6 hours after saline injection in old skin were also induced by
VZV antigen challenge at the same time point (Fig 4, C, and
see Fig E6). These data indicate that the early transcriptional
response to VZVantigen challenge in the skin of old subjects in-
cludes an inflammatory component that might not be specific for
the antigen itself.
We investigated whether the propensity to exhibit sterile
inflammatory responses at 6 hours after nonspecific (saline-
induced) inflammation in aging skin was directly associated with
decreased clinical response to VZV challenge in the contralateral
arm of the same subjects at 48 hours. To address this, the
expression levels of 384 genes designated as positive regulators of
the inflammatory response (see Table E8 in this article’s Online
Repository at www.jacionline.org) were compared in the skin
of young (n5 6) and old (n5 10) subjects at 6 hours after saline
injection. By using gene set variation analysis, each subject wasrelated to p38 MAP kinase signaling. D, Bubble plot sh
versus normal skin. Kyoto Encyclopedia of Genes an
curated skin-related collection, were interrogated, and
false discovery rate of less than 0.05 are presented. E,
(see the Methods section) and plotted against VZV clin
subjects, n 5 10).assigned a numeric score (denoted as the inflammatory index)
based on the variation in expression of all these inflammatory
genes. A highly significant inverse correlation was observed
when the inflammatory index value to saline injection for each
subject was plotted against the clinical response to intradermal
VZV antigen challenge in the contralateral arm (Fig 4, E).
A similar and significant inverse correlation was observed be-
tween expression levels of IL-1b, IL-6, IL-12p35, and
IL-12p40, as determined by using quantitative RT-PCR and a sub-
ject’s clinical response to VZVantigen challenge were compared
(see Fig E7 in this article’s Online Repository at www.jacionline.
org). This indicates an association between the propensity to
exhibit early sterile inflammation and reduced responses to
VZVantigen challenge in the skin of the same old subjects in vivo.Nonspecific inflammation induced by saline
injection is associated with mononuclear
phagocytes
The DEGs identified at 6 hours after saline injection (false
discovery rate < 0.05, fold change > 2; see Table E2) were im-
ported into BioLayout Express3D to identify the cell type that
might contribute to the increased proinflammatory response to sa-
line injection in aging skin (see theMethods section and Fig 5, A).
Comparison of the mean cellular expression profiles of the gene
clusters derived from this network graph suggested that many
of the genes within them were strongly associated with cells of
the monocyte/macrophage lineage (Fig 5, A, and see Table E9
in this article’s Online Repository at www.jacionline.org).
Furthermore, immunohistologic analysis also demonstrated a
significant increase in the number of CD1631 mononuclear
phagocytes in the skin of old subjects within 6 hours of saline in-
jection (Fig 5,B andC). This was confirmed by usingmultiparam-
eter flow cytometry, in which we identified significantly increased
proportions of HLA-DR1CD141mononuclear phagocytes in old
compared with young skin biopsy specimens 6 hours after saline
injection (Fig 5, D, and see Fig E8 in this article’s Online
Repository at www.jacionline.org). This rapid increase in the
frequency of CD14-expressing mononuclear phagocytes was
probably a result of recruitment from the blood because these
cells were not in cycle (data not shown).23 The increase in
‘‘inflammatory’’ monocytes in old subjects was transient and
coincided with the transient sterile inflammatory response that
was only observed at 6 but not 24 hours after saline injection.
A similar significant transient increase in numbers of
mononuclear phagocytes was observed when old subjects were
injected with VZV (see Fig E4, E).Short-term p38 MAP kinase blockade improves
clinical response to VZV skin challenge in older
subjects
We tested the hypothesis that excessive proinflammatory
cytokine secretion is driven by p38 MAP kinase signaling in
mononuclear phagocytes early in the skin response. To do this, weows expression of pathways in saline-injected skin
d Genomes (KEGG) and GO collection, as well as
the most relevant pathways among them with an
Inflammatory index was calculated for each subject
ical scores at 72 hours (young subjects, n 5 6; old
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response to VZV challenge (clinical score, <4) with Losmapi-
mod, a potent and selective oral p38MAP kinase inhibitor, before
VZVantigen rechallenge in the skin (Fig 6,A).15,16 These subjects
were investigated 2 to 3 months after the first skin test and pre-
treated with the drug for 4 days before rechallenge with VZVan-
tigen in the skin. In parallel studies we showed that rechallenge of
old volunteers with VZV skin test antigens did not significantly
boost their original clinical scores (n 5 14, P 5 .58, see Fig E9
in this article’s Online Repository at www.jacionline.org).
CRP production in the liver is upregulated by p38MAPkinase–
dependent cytokines, such as IL-1 and IL-6.24,25 Serum CRP
levels were significantly reduced after Losmapimod pretreatment
(P 5 .04, n 5 18; Fig 6, B). In addition, TNF-a, IL-6, and IL-8
production by LPS-stimulated PBMCs from the same donors
was also significantly reduced after Losmapimod pretreatment
(Fig 6, C, and see Fig E10 in this article’s Online Repository at
www.jacionline.org). In contrast, Losmapimod pretreatment
significantly enhanced the clinical response to VZVantigen chal-
lenge in the skin of 13 of 18 old subjects (n5 18,P5 .0006; Fig 6,
D). This increase in clinical score to VZV challenge correlated
with the decrease in CRP levels in serum in the same subjects
(Fig 6, E). Losmapimod pretreatment had no effect on CD41 or
CD81 T-cell function in response to CD3 and IL-2 stimulation
in the same donors, as defined by cytokine expression (IFN-g,
IL-2, and TNF-a) or proliferation, as defined by Ki67 expression
(see Fig E10). Histological assessment of biopsy specimens
collected from 4 old subjects with an increased clinical response
after Losmapimod treatment showed that there was a significant
increase in the number of CD11c1 DCs in the perivascular infil-
trates (P 5 .04) that were associated with increased numbers of
CD41 T cells in immune clusters (representative experiment
shown in Fig 6, F, top and bottom right panels). These clusters
were not found in 4 of the subjects who did not respond to Losma-
pimod treatment (Fig 6,F, top and bottom left panels). These clus-
ters resembled those found after VZV challenge of skin in young
subjects (Fig 2). This shows that p38 MAP kinase inhibition
significantly reduced proinflammatory responses and that this
was associated with enhancement of antigen-specific immune re-
sponses in the skin of old subjects in vivo.DISCUSSION
The cutaneous recall response to intradermal antigen challenge
is a manifestation of immunememory, and this reaction decreases
with age.4,26-28 We have investigated reasons for this decrease to
explain the increased incidence of cutaneous infection and malig-
nancy during aging.2,29 Early inflammation (erythema and indu-
ration in 48 hours) is required to initiate the cascade of events
leading to optimal cellular infiltration in the skin that occurs later
(peak at 7 days).14 Therefore an unexpected observation was that
excessive inflammation during the early phase after VZV chal-
lenge hinders the amplification of the response in old subjects.
The response to VZV in older subjects is not inhibited from the
outset because the endothelium of old and young subjects is acti-
vated equally at 6 hours, and gene expression at this time is
similar. Furthermore, the decreased response after VZV antigen
challenge in these subjects was not due to intrinsic changes in
the functionality of cutaneous TRM cells or macrophages because
these cells from both age groups were equally responsive when
isolated from skin and activated in vitro.4,11In other studies increased systemic inflammation has been
shown to have a negative effect on the cutaneous recall response
to Candida species antigens30; however, this study did not inves-
tigate the response of old subjects or events that occur in the skin
itself. The reduced efficacy of vaccination has also been linked to
excessive inflammation for influenza,31 yellow fever,32 tubercu-
losis,33 and hepatitis B34 vaccines. Furthermore, inflammatory
macrophages in patients with chronic artery disease suppress T-
cell activation and expansion in vitro, and this is associated
with defective VZV-specific T-cell immunity in the peripheral
blood of these patients.35 The proposed mechanism for this inhi-
bition involves the upregulation of the inhibitory receptor ligand
programmed death ligand 1 on the inflammatory macrophages
that inhibit function of programmed cell death protein 1–express-
ing T cells.35 This suggests that the infiltration of inflammatory
monocytes that express programmed death ligand 1 during sterile
inflammation might block early activation of cutaneous TRM cells
because this latter population expresses significantly higher levels
of PD-1 during aging.11
Type I interferon has been shown to interfere with antigen-
specific T-cell responses, and excessive levels of these mediators
impair the clearance of both viral and mycobacterial infections in
mice in vivo.36,37 In the present study we also found a strong type I
interferon signature in the skin of old subjects after saline injec-
tion, although other inflammatory pathways were also upregu-
lated. The effect of excessive inflammation on inhibition of
antigen-specific T-cell function is particularly important for aging
because older subjects have widespread low-grade systemic
inflammation termed ‘‘inflammaging’’12 that is linked to expres-
sion of inflammasome gene modules that might underpin clinical
frailty and immune dysfunction.13
It is not clear why saline injection induces early but transient
inflammation in the skin of old subjects (observed at 6 but not
24 hours after injection). However, NaCl itself is proinflammatory
and has been shown to induce TH17 cells while conversely inhib-
iting forkhead box protein 31 regulatory T-cell function38,39 and
to also activate inflammatory cascades in monocytes and bone
marrow–derived macrophages in vitro.40,41 The saline control
that we used in the current study contained 0.9% NaCl, which
is similar to the concentration used in the diluent of the VZV
skin test antigen (0.68% NaCl). Therefore a component of the
transcriptional response of old subjects to VZV antigen would
also include a response to NaCl in the diluent that might hinder
the induction of antigen-specific immunity in old subjects. This
response is not observed in young subjects. We identified mono-
nuclear phagocytes as the source of the saline-induced cutaneous
inflammation.
Many of the inflammatory mediators induced by saline injec-
tion in older subjects were linked directly or indirectly to
activation of the p38 MAP kinase pathway. Many pharmaceutical
companies have tested small-molecule p38 MAP kinase in-
hibitors in human subjects in vivo in phase I, II, and III trials to
block inflammatory diseases/disorders.42 Although most trials
with p38 MAP kinase inhibitors were discontinued because of
hepatotoxicity after long-term treatment (>3 months) and adapta-
tion of cell-signaling pathways, leading to reduced drug effi-
cacy,43 these inhibitors do not show evidence of toxicity in the
short-term (weeks) in human subjects in vivo. Therefore we
treated old subjects who were not responsive to cutaneous VZV
antigen challenge with Losmapimod (GW856553), a selective,
reversible, competitive inhibitor of p38 MAP kinase, to test the
FIG 5. Identificationofamonocyte/macrophage-relatedgeneexpressionsignature insaline-injectedagedskin.A,
Transcriptomicanalysisusing the toolBioLayoutExpress3Dofgenesupregulated in theskinofelderlyhumansub-
jects 6 hours after saline treatment, which clusters together in a large network of monocyte/macrophage-related
genes (C_, cluster no.; nodes represent individual genes, and edges represent Pearson correlations > 0.7). B and
C, Representative images of CD163-stained saline-injected skin from skin from young and old subjects (CD163
is pink, Dapi blue; Fig 5, B) and cumulative data of CD1631 cells in paired analysis from normal and saline-
injected skin at 6 hours (Fig 5,C; n5 4-5 per age group). *P < .05.D, Frequency ofmononuclear phagocytes deter-
minedasbeingCD451 Lineage2 (CD32, CD192,CD202, andCD562) andHLA-DR1 andeitherCD141 and/orCD161
expressed as a percentage of CD451 Lineage2 cells in young (open symbols) and old (solid symbols) subjects
before and after saline, as assessed by using flow cytometry. Data are assessed by using the paired t test.
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FIG 6. Effects of Losmapimod treatment on VZV response in the skin. A, Responses to VZV skin challenge were
investigated in old subjects (n 5 18, 8 male and 10 female subjects) before and after Losmapimod treatment
(15 mg administered twice daily for 4 days). B, Serum CRP levels before and after Losmapimod treatment
(n5 18; P5 .04,Wilcoxon paired test).C,Whole-blood LPS stimulationwas performed before and after Losmapi-
mod treatment, and TNF-a production wasmeasured by using CBA (LPS: P < .0001 and Losmapimod: P < .0001,
2-way ANOVA [n5 18]).D, Clinical score wasmeasured at 48 hours after VZV antigen challenge before and after
Losmapimod (P5 .0006,Wilcoxon paired test; red symbols indicate themean). E,Correlation between change in
serumCRP level and change in clinical score after Losmapimod treatment (Pearson correlation).F,Representative
images of skin sections collected 7 days after VZV injection stained for CD4 (red) andCD11c (pale blue) before and
after Losmapimod treatment in one of the subjects with an increased clinical score in response to VZV improved
after Losmapimod treatment (top and bottom right panels) and one of the subjectswhose clinical score remained
low after Losmapimod treatment (top and bottom left panels).White arrows indicate a DC interacting with sur-
rounding T cells.
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antigen-specific cutaneous immunity. The key observation was
that Losmapimod pretreatment significantly enhanced the cuta-
neous response to VZV in older subjects. Although our previous
studies have shown that that p38 inhibition can enhance T-cell
proliferation in vitro,44-46 in the current study Losmapimod treat-
ment did not affect peripheral blood T-cell proliferation or cyto-
kine production after stimulation with CD3/IL-2. Thus the
enhancement of cutaneous immunity is likely to be due to the
anti-inflammatory effects of the drug.
This raises the question of whether the short-term inhibition of
p38 MAP kinase signaling and/or inhibition of inflammation
would also enhance immunity in other tissues. An interesting
possibility is that this would be a strategy to improve vaccine
efficacy that is decreased in aging subjects.3,47 Another point to
consider is that increasing the strength of adjuvants to enhance
vaccine responses during aging might be counterproductive if
they further increase inflammatory responses, and it might be
important to stratify old vaccinees on the basis of their baseline
inflammatory responses in the future.13 Our study might appear
to challenge the concept that antigen-specific immunization is
more successful in the presence of an adjuvant that is designed
to increase inflammatory responses. However, although adjuvants
can enhance induction of immunity in draining lymph nodes,
excessive inflammation that is present at the site of the effector
phase of a response might inhibit T-cell responsiveness. This
could be a mechanism to protect against pathology induced by
excessive immune stimulation in the tissues. Furthermore, exces-
sive inflammation is detrimental for cancer progression,48 and the
temporary inhibition of inflammation in this situation might be a
strategy for boosting immunotherapy in these patients. Although
the current challenge is to identify the optimal way to reduce
excessive inflammation and to enhance immunity in aging human
subjects, it is serendipitous that some drugs that might do this
have already been developed and therefore can be repurposed.
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